<DOC>
	<DOC>NCT00199095</DOC>
	<brief_summary>The aim of this study is to test feasibility and efficacy of a dose reduced chemotherapy in elderly patients with newly diagnosed acute lymphoblastic leukemia. The regimen consists of induction phase I and II followed by cyclic consolidation cycles, reinduction and maintenance therapy</brief_summary>
	<brief_title>Treatment of Elderly Patients (&gt;65 Years) With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>diagnosis of acute lymphoblastic leukemia (proB,common,preB,preT,Thy,mature T, BALL) age &gt; 65 years written informed consent Karnofsky &gt; 50% (if not mainly caused by leukemia) laboratory at diagnosis or after supportive pretreatment Creatinine &lt; 2 mg/dl Uric Acid &lt; 8 mg/dl Bilirubin &lt; 1.5 mg/dl ALA, ASA,AP &lt; 2.5 x ULN severe second diseases (e.g. renal failure, cardiomyopathy etc., not caused by leukemia) that exclude treatment according to the protocol severe psychiatric illness or other circumstances which may compromise cooperation active second neoplasia clinical signs of life threatening infections or bleeding, uncontrollable prior to chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Elderly</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>